Huntington's Disease
FDA/CDC
Austedo approved for treatment of tardive dyskinesia
The drug was also approved in April 2017 to treat chorea associated with Huntington’s disease.
FDA/CDC
FDA approves deutetrabenazine for Huntington’s-associated chorea
Deutetrabenazine is only the second product approved to treat Huntington’s in any capacity, and it is the first in nearly a decade.
News
Intermediate alleles may confer mild, late-onset Huntington-like symptoms
Key clinical point: Asymptomatic people who carry an intermediate number (27-35) of CAG repeats on the huntingtin gene may be at increased risk...
News
Deutetrabenazine modestly reduces chorea of Huntington disease
A deuterated form of the vesicular monoamine transporter type 2 inhibitor tetrabenazine appears to modestly reduce chorea of Huntington disease...